Literature DB >> 22798229

Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors.

Qinggang Hu1, Shanglong Liu, Jianwei Jiang, Chen Zhang, Xiaowei Liu, Qichang Zheng.   

Abstract

In order to find out the potential indicators predicting prognosis of malignant gastrointestinal stromal tumors (GISTs) after surgical resection, we collected clinical records of 80 patients with malignant GISTs. Tumor location, size, mitotic index, necrosis were compared with the prognosis of malignant GISTs by Kaplan-Meier method and log-rank test. After a median follow-up of 844 days (52-2 145), we found that as National Institutes of Health suggested, tumors with intermediate risk had more favorable prognosis than that with high risk. Their 3-year survival rate were 65.3% and 41.3%, respectively (P < 0.001). Moreover, tumor size and mitotic index were associated with free survival. The 3-year survival rate for patients with tumor size ≤ 10 cm and > 10 cm were 62.3% and 41.8%, respectively (P = 0.002), Tumors with mitotic index ≤ 5/50 HPF had a higher 3-year survival rate than tumors with mitotic index > 5/50 HPF (67.1% versus 40.7%, P = 0.005). The presence of necrosis was directly related to the malignant behavior. The 3-year survival rate for presence and absence necrosis were 50.8% and 64.8% (P = 0.008). From the present study, we can conclude that besides tumors size and mitotic index, tumor location and necrosis also influence on the long-term survival of patient with malignant GISTs after surgical resection.

Entities:  

Mesh:

Year:  2012        PMID: 22798229     DOI: 10.1007/s11684-012-0203-9

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  29 in total

1.  Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; J-Y Blay
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.

Authors:  Yoshinari Mochizuki; Yasuhiro Kodera; Seiji Ito; Yoshitaka Yamamura; Yukihide Kanemitsu; Yasuhiro Shimizu; Takashi Hirai; Kenzo Yasui; Ken-ichi Inada; Tomoyuki Kato
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

3.  KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist.

Authors:  Katerina Kontogianni-Katsarou; Constantina Lariou; Eugenia Tsompanaki; Christina Vourlakou; Evi Kairi-Vassilatou; Costas Mastoris; Georgia Pantazi; Agatha Kondi-Pafiti
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  Prognostic impact of blood vessel invasion in gastrointestinal stromal tumor of the stomach.

Authors:  Hidetaka Yamamoto; Aya Kojima; Yoshihiro Miyasaka; Masakazu Imamura; Norimoto Nakamura; Takashi Yao; Masazumi Tsuneyoshi; Yoshinao Oda
Journal:  Hum Pathol       Date:  2010-06-22       Impact factor: 3.466

Review 5.  Gastrointestinal stromal tumor: 5 years later.

Authors:  Sanne M van der Zwan; Ronald P DeMatteo
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

6.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

7.  Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.

Authors:  Imran Hassan; Y Nancy You; Roman Shyyan; Eric J Dozois; Thomas C Smyrk; Scott H Okuno; Cathy D Schleck; David O Hodge; John H Donohue
Journal:  Ann Surg Oncol       Date:  2007-11-14       Impact factor: 5.344

Review 8.  Management of gastrointestinal stromal tumors.

Authors:  Matthew T Hueman; Richard D Schulick
Journal:  Surg Clin North Am       Date:  2008-06       Impact factor: 2.741

9.  Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.

Authors:  Martin E Blackstein; Jean-Yves Blay; Christopher Corless; David K Driman; Robert Riddell; Denis Soulières; Carol J Swallow; Shailendra Verma
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.